GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoNex Inc (ROCO:4168) » Definitions » EV-to-FCF

GlycoNex (ROCO:4168) EV-to-FCF : -9.97 (As of May. 25, 2024)


View and export this data going back to 2012. Start your Free Trial

What is GlycoNex EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, GlycoNex's Enterprise Value is NT$2,055.28 Mil. GlycoNex's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-206.05 Mil. Therefore, GlycoNex's EV-to-FCF for today is -9.97.

The historical rank and industry rank for GlycoNex's EV-to-FCF or its related term are showing as below:

ROCO:4168' s EV-to-FCF Range Over the Past 10 Years
Min: -672.25   Med: -10.61   Max: -1.22
Current: -9.97

During the past 13 years, the highest EV-to-FCF of GlycoNex was -1.22. The lowest was -672.25. And the median was -10.61.

ROCO:4168's EV-to-FCF is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 8.36 vs ROCO:4168: -9.97

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), GlycoNex's stock price is NT$24.90. GlycoNex's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-1.770. Therefore, GlycoNex's PE Ratio for today is At Loss.


GlycoNex EV-to-FCF Historical Data

The historical data trend for GlycoNex's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoNex EV-to-FCF Chart

GlycoNex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.54 -15.64 -17.21 -15.93 -12.16

GlycoNex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.54 -14.69 -10.61 -12.16 -9.92

Competitive Comparison of GlycoNex's EV-to-FCF

For the Biotechnology subindustry, GlycoNex's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoNex's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoNex's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where GlycoNex's EV-to-FCF falls into.



GlycoNex EV-to-FCF Calculation

GlycoNex's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2055.278/-206.045
=-9.97

GlycoNex's current Enterprise Value is NT$2,055.28 Mil.
GlycoNex's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-206.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlycoNex  (ROCO:4168) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

GlycoNex's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=24.90/-1.770
=At Loss

GlycoNex's share price for today is NT$24.90.
GlycoNex's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1.770.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


GlycoNex EV-to-FCF Related Terms

Thank you for viewing the detailed overview of GlycoNex's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoNex (ROCO:4168) Business Description

Traded in Other Exchanges
N/A
Address
Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221
GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies which targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability and can serve as reagent with applications that include ELISA, Western blot, flow cytometry, TLC immunostaining, and IHC. The group also provides antibody research service to its academic and industrial clients. The other services provided by the firm include functional evaluation, antibody engineering, and antibody characterization.

GlycoNex (ROCO:4168) Headlines

No Headlines